The Company and Summary of Significant Accounting Policies (Details)	3 Months Ended				12 Months Ended	287 Months Ended		3 Months Ended	12 Months Ended	3 Months Ended
	Mar. 31, 2014 USD ($)	Mar. 31, 2014 EUR (€)	Mar. 31, 2013 EUR (€)	Mar. 31, 2012	Dec. 31, 2013 USD ($)	Mar. 31, 2014 EUR (€)	Dec. 31, 2013 EUR (€)	Mar. 31, 2014 Accounts Receivable [Member]	Dec. 31, 2003 Accounts Receivable [Member]	Mar. 31, 2014 Convertible Loans [Member]	Mar. 31, 2013 Convertible Loans [Member]	Mar. 31, 2012 Convertible Loans [Member]	Mar. 31, 2014 Shares Issuable to Norwood [Member]	Mar. 31, 2014 Warrants [Member]	Mar. 31, 2012 Warrants [Member]	Mar. 31, 2014 Stock Options [Member]	Mar. 31, 2013 Stock Options [Member]	Mar. 31, 2012 Stock Options [Member]
BASIS OF PRESENTATION [Abstract]
Deficit accumulated during the development stage		€ 65,074,000				€ 65,074,000	€ 64,165,000
Amount of current liabilities exceed its current assets		37,047,000				37,047,000
Deferred Revenue Arrangement [Line Items]
Period to earn royalty payments after first commercial sale	10 years	10 years
Upfront fee for license received	5,000,000	0	0			4,381,000
Milestone payments received	62,000,000
PROPERTY AND EQUIPMENT [Abstract]
Estimated useful lives	3 years	3 years
Contingent Consideration [Abstract]
Issuance of shares to settle continent liability (in shares)	5,338,809	5,338,809				5,338,809
TAXES ON INCOME [Abstract]
Income tax contingency open tax years	December 31, 2009 to 2013	December 31, 2009 to 2013
EARNINGS PER SHARE [Abstract]
Weighted average number of shares (in shares)	298,418,813	298,418,813	295,318,813	286,834,649
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total potential number of shares issuable (in shares)	482,820,942	482,820,942	123,808,700	145,545,352						456,632,133	87,490,712	89,634,402	5,338,809	32,684,488	51,218,450	20,850,000	3,633,500	4,692,500
Shares included in the weighted average number of dilutive shares (in shares)	13,915,309	13,915,309
PREFERRED STOCK [Abstract]
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000				5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0				0	0
Preferred stock, shares outstanding (in shares)	0	0				0	0
STOCK-BASED COMPENSATION [Abstract]
Shares issued to individuals as fee for services rendered (in shares)	0	0	0
Incentive stock options awarded (in shares)					20,600,000
Exercise price of shares granted (in dollars per share)					$ 0.02
Shares vested (in shares)							3,300,000
Shares exercised (in shares)					3,100,000
Number shares of unvested common stock (in shares)							17,300,000
Vesting period of stock options					4 years
Stock based compensation expense		28,000	1,000
Concentration Risk [Line Items]
Concentration percentage								80.00%	98.00%
RELATED PARTY TRANSACTIONS [Abstract]
Professional fees to counsel's law firm		23,000	86,000
COMMITMENTS [Abstract]
Period of agreement of license rights	5 years	5 years
Annual fee for license rights		200,000
Expiration date of license right	Dec. 23, 2013	Dec. 23, 2013
Amount still due to PX Therapeutics		€ 100,000